

INNOVATIVE CARE FOR EVERY DIALYSIS PATIENT

Advanced membrane designs
supporting all hemodialysis
therapy options



ENSURING YOU HAVE THE TOOLS, TRAINING AND SUPPORT YOU NEED

Vantive has been a full-service provider for more than 60 years and we remain committed to helping you achieve the best outcomes possible for both home and in-center dialysis.



TRAINING:

To help ensure that everyone in your clinic understands their preferred dialyzer and the benefits it delivers, we provide you with:

- > Technical and product training
- > Therapy training
- > Scientific and research partnership
- > Tailored in-service planning



SUPPORT:

In addition to our local and expert sales and clinical teams, Vantive offers direct support at all times:


- > Technical support (call-in)
- > Renal Clinical Helpline
 - offering real-time support during business hours
- > On-site technical/repair services



DELIVERY:

We have the capabilities of supporting your dialysis unit through our strong global supply chain, local distributors and delivery network:

- > Customer service (order support)
- > Direct deliveries



PIONEERS & INNOVATORS IN RENAL CARE

HELPING SAVE AND SUSTAIN LIVES

At Vantive, our mission is to save and sustain lives. We believe we can achieve this by providing healthcare professionals with an innovative portfolio of dialyzers that empowers them to deliver the right therapy, for the right patient.

As the pioneering innovator in dialyzer technology, we have developed a unique expertise in membrane design in relation to toxin removal by dialysis. Each of our dialyzers has a unique membrane that has been designed for the needs of a specific therapy and patient population while delivering safe and effective removal of a wide range of uremic solutes.



A PORTFOLIO OF DIALYZERS TO MEET INDIVIDUAL NEEDS

Our technological advances in membrane design and our deep understanding of each renal therapy has allowed us to create a portfolio of advanced dialyzers. Each dialyzer brand is unique in the way it meets the requirements of renal therapies performance, but it benefits from Vantive’s tradition and expertise in performance, quality and simplicity.

HFHD

HIGH FLUX HD

OPTIMIZING
HIGH FLUX
PERFORMANCE



DESIGNED FOR
HIGH FLUX HD

Revaclear

The **Revaclear** dialyzer series is a range of high efficiency high-flux dialyzers designed to enhance safety and biocompatibility for your patients, while optimizing clearance with a smaller surface area:⁴

HDF-HF

CONVECTIVE THERAPIES

FOR EFFECTIVE
CONVECTIVE
THERAPIES



DESIGNED FOR
CONVECTIVE THERAPIES

Polyflux H

The **Polyflux** H dialyzer series deliver proven biocompatibility⁵ and endotoxin retention³ with consistent performance. The **Polyflux** H dialyzers effectively support the delivery of high-volume convective therapies⁹ while helping control the loss of essential proteins such as albumin⁷, particularly challenging at high flows and TMPs.

HDx

EXPANDED HEMODIALYSIS

PROVIDE EXPANDED HD
RETAIN HD SIMPLICITY



DESIGNED FOR
EXPANDED HEMODIALYSIS

Theranova

The HDx therapy is enabled by the **Theranova*** dialyzer series, featuring an innovative membrane design that combines a higher permeability than regular high-flux dialyzers with effective selectivity for large proteins^{8,9}

SPECIAL

THERAPEUTIC APPLICATIONS

Polyflux 2H/6H

SPECIALIZED FOR LOW BODY
WEIGHT PATIENTS

The **Polyflux** 2H/6H dialyzer series enables high flux dialysis compatibility and performance to low body weight patients, typically children.^{5,10,11}

Nephral ST

SPECIALIZED FOR HIGH BIO-
COMPATIBILITY AND ADSORPTION

The **Nephral** ST dialyzer series features a heparin adsorptive hydrogel membrane, for a reduced use of systemic heparin during dialysis. The membrane is designed to provide effective removal of uremic toxins and inflammatory mediators by adsorption.¹²

Evodial

SPECIALIZED FOR HIGH
BLEEDING RISK PATIENTS

The **Evodial**** dialyzer series is specialized for patients with a high risk of bleeding.^{13,14} It has been designed with the **HeprAN** heparin grafted membrane,^{12,15} and provides a convenient solution for patients requiring reduced or even heparin-free dialysis.¹³

Theralite

SPECIALIZED FOR MULTIPLE
MYELOMA PATIENTS

The **Theralite***** dialyzer, featuring the proprietary High Cut-Off (HCO) membrane, targets the removal of free light chain (FLC) proteins when needed in patients with multiple myeloma cast nephropathy experiencing renal failure.^{16,17}

* Do not use **Theranova** dialyzers in HDF or HF mode.
** Do not use **Evodial** in patients with a known allergy to heparin or type II thrombocytopenia caused by heparin (HIT type II).
*** Do not use **Theralite** dialyzers in HDF or HF mode .
*** **Theralite** dialyzers must not be used for pediatric dialysis and for regular treatment of chronic renal failure.
*** **Theralite** dialyzers must only be used on the direction of a physician who has evaluated all the pertinent features of this device in relation to the individual patient.


THERAPY INNOVATIONS DRIVEN BY MEMBRANE DESIGN

Dialysis therapies have progressed through time, primarily along dialyzer membrane innovations and advancements.

Dialyzer membrane design is defined by both its physical and chemical structure. A dialyzer membrane’s capability to remove molecules depends on these structures and the therapy, or form of fluid transport mechanism, being performed.

However, for both diffusive and convective therapies, the membrane’s effective pore size distribution determines the molecular weight of the uremic toxins that can be removed safely and efficiently.

Today, a range of therapies and specific dialyzers are available to address dialysis patients’ personal needs for safe and effective uremic toxin removal.



Classification of uremic solutes by molecular weight (Daltons).^{1,2}

REFERENCES

1. Wolley M et al. Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules. *Clin J Am Soc Nephrol* 2018;13:805-814.
2. Vanholder R et al. Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. *Toxins* 2018;10,33 (doi:10.3390/toxins10010033).
3. Schepers E, Glorieux G, Eloot S, et al. Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up. *BMC Nephrology*. 2018;19:1.
4. Vantive. REVACLEAR White Paper. USMP/MG3/140052, May 2013.
5. Ronco C, et al. Evolution of synthetic membranes for blood purification: the case of the Polyflux family. *Nephrol Dial Transplant* 2003;18 (Suppl 7):vii10–20.
6. Maduell F, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *J Am Soc Nephrol*. 2013;24:487-497.
7. Potier J et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *Int J Artif Org* 2016;39:460-70.
8. Boschetti-de-Fierro A, et al. MCO membranes: Enhanced Selectivity in High-Flux Class. *Scientific Reports* 2015;5:18448.
9. Zweigart C, et al. Medium cut-off membranes – closer to the natural kidney removal function. *Int J Artif Organs* 2017; 40(7):328-334.
10. Goldstein SL, et al. Polyflux 6H dialyzer: a new option for small children requiring dialysis. *Int J Artif Organs* 2007; 30:321–324.
11. Warady BA, et al. Pediatric Dialysis. Chapter 19. Maintenance hemodialysis during infancy. 2012. Edited by Ulinski T, Cochat P.
12. Thomas M, et al. AN69: Evolution of the world’s first high permeability membrane AN69: Evolution of the world’s first high permeability membrane. *Contrib Nephrol* 2011;173:119–129.
13. Laville M, et al. Results of the HepZero study. *Kidney Int* 2014;86:1260–1267.
14. Kessler M, et al. Anticoagulation in chronic hemodialysis: progress toward an optimal approach. *Semin Dial* 2015;28:474–489.
15. Chanard J, et al. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. *Nephrol Dial Transplant* 2008;23:2003–2009.
16. Boschetti-de-Fierro A, et al. Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. *Int J Artif Organs* 2013;36:455–463.
17. Hutchison CA, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. *Nat Rev Nephrol* 2012;8:43–51.

For safe and proper use of the device, please refer to the Instructions for Use.

Vantive, Evodial, HeprAN, Nephral, Polyflux,
Revaclear, Theralite and Thernova are trademarks
of Vantive Health LLC or its affiliates.

CA-RC46-250001(V1.0) 03/2025

Vantive ULC
6675 Millcreek Drive, Unit 2
Mississauga ON L5N 5M4
Canada
www.vantive.com